PROVIDER BULLETIN Provider information



June 18, 2013

July 2013 HCPCS code updates

In compliance with HIPAA requirements, effective with dates of service on or after July 1, 2013, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will accept the quarterly Level II (alphanumeric) HCPCS and CPT additions and revisions published by the Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA). Added codes will be rejected if submitted with a date of service before July 1, 2013. Likewise, discontinued codes will be rejected if submitted with a date of service on or after July 1, 2013.

Code list

HCPCS codes are generally only published once a year; however, CMS or AMA may publish added, revised and/or deleted codes on a quarterly basis. As a courtesy to our providers, we are publishing the added, revised and discontinued codes below.

Added codes:

| Code | Narrative |
|-------|--|
| JE | Administered Via Dialysate |
| C9131 | Injection, ado-trastuzumab emtansine, 1 mg |
| C9736 | Laparoscopy, surgical, radiofrequency ablation of uterine fibroid(s), including intraoperative |
| | guidance and monitoring, when performed |
| G0460 | Autologous platelet rich plasma for chronic wounds/ulcers, including phlebotomy, |
| | centrifugation, and all other preparatory procedures and administration, per treatment |
| K0008 | Custom Manual Wheelchair Base |
| K0013 | Custom Motorized/Power Wheelchair Base |
| K0900 | Customized Durable Medical Equipment, Other Than Wheelchair |
| Q0090 | Levonorgestrel-Releasing Intrauterine Contraceptive System (SKYLA), 13.5 mg |
| Q2033 | Influenza Vaccine, Recombinant Hemagglutinin Antigens, For Intramuscular Use (Flublok) |
| Q2050 | Injection, Doxorubicin Hydrochloride, Liposomal, Not Otherwise Specified, 10mg |
| Q2051 | Injection, Zoledronic Acid, Not Otherwise Specified, 1mg |
| 0001M | Infectious disease, HCV, six biochemical assays (ALT, A2 macroglobulin, apolipoprotein A 1, |
| | total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores |
| | for fibrosis and necroinflammatory activity in liver |
| 0002M | Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total |
| | bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, |
| | prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic |
| | steatohepatitis (ASH) |
| 0003M | Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total |
| | bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, |
| | prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic |
| | steatohepatitis (NASH) |
| 0004M | Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, |
| | prognostic algorithm reported as a risk score |

Continued on back

| Code | Narrative |
|-------|--|
| 0005M | Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using |
| | maternal plasma, algorithm reported as a risk score for each trisomy |
| 0329T | Monitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with |
| | interpretation and report |
| 0330T | Tear film imaging, unilateral or bilateral, with interpretation and report |
| 0331T | Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; |
| 0332T | Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; |
| | with tomographic SPECT |
| 0333T | Visual evoked potential, screening of visual acuity, automated |
| 0334T | Sacroiliac joint stabilization for arthrodesis, percutaneous or minimally invasive (indirect |
| | visualization), includes obtaining and applying autograft or allograft (structural or morselized), |
| | when performed, includes image guidance when performed (eg, CT or fluoroscopic) |

Revised codes (added narrative underlined; deleted narrative struck through):

| Code | Narrative |
|-------|---|
| C9734 | Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with or |
| | without magnetic resonance (MR) guidance |
| Q0509 | Miscellaneous Supply Or Accessory For Use With Any Implanted Ventricular Assist Device |
| | For Which Payment Was Not Made Under Medicare part A |
| Q5001 | Hospice Or Home Health Care Provided In Patient's Home/Residence |
| Q5002 | Hospice Or Home Health Care Provided In Assisted Living Facility |
| Q5009 | Hospice Or Home Health Care Provided In Place Not Otherwise Specified (NOS) |

Discontinued code:

CodeNarrativeC1879Tissue marker (implantable)

Coding requirements reminder

All coding and reimbursement is subject to changes, updates or other requirements of coding rules and guidelines. All codes are subject to federal HIPAA rules, and in the case of medical code sets (for example, HCPCS, CPT, ICD-9-CM), only valid codes for the date of service may be submitted or accepted.

Questions?

If you have questions, please contact provider services at (651) 662-5200 or toll free at 1-800-262-0820.

HCPCS stands for Health Care Procedure Coding System CPT[®] (Current Procedural Terminology) is a registered trademark of the American Medical Association ICD-9-CM stands for International Classification of Diseases 9th revision Clinical Modification